|
Dr. Teitelbaum has over fifteen years of experience in oncology drug development, with roles of increasing responsibility in both biotech and pharmaceutical organizations. She joined Amgen after a career as a clinical investigator in clinical practice. More recently, Dr. Teitelbaum was the Vice President of Clinical Research and Development for Kyowa Pharmaceuticals, U.S. She previously held positions at Johnson & Johnson, Ligand, Titan Pharmaceuticals and Sequus Pharmaceuticals. She has maintained clinical appointments and faculty status at USC, UCLA, Harvard, and Stanford. She received her B.S. in Biology from the College of William and Mary, her M.D. from Rush Medical College, and an M.S. from NYU School of Medicine (Erythropoietin Physiology). Dr. Teitelbaum is a Diplomat, American Board of Internal Medicine, Hematology and Medical Oncology. | 